Neutrally charged phosphorodiamidate Morpholino antisense oligomers: Uptake, efficacy and pharmacokinetics

Current Pharmaceutical Biotechnology

Volumn 5, Issue 5, 2004, Pages 431-439

  Arora, Vikram ^a   Devi, Gayathri R ^a   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

C myc; Cancer; Delivery; Fluorescence; Genomics; Phosphorothioate; PMO; Prostate

Indexed keywords

AFOVIRSEN; ALICAFORSEN; ALPHA5 INTEGRIN; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; AVI 4020; AVI 4126; AVI 4472; AVI 4557; CGP 69846A; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; DNA; GELATINASE A; GELATINASE B; ISIS 2503; ISIS 3521; MORPHOLINE DERIVATIVE; MYC PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGOMER; PHOSPHORIC ACID DERIVATIVE; PROTEIN P53; RNA DERIVATIVE; SINGLE STRANDED DNA; SOMATOMEDIN C RECEPTOR; TRECOVIRSEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; BLOOD VESSEL INJURY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TISSUE LEVEL; DRUG UPTAKE; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENE TECHNOLOGY; GLIOBLASTOMA; HEPATITIS C; HUMAN; HUMAN GENOME; IC 50; IN VIVO STUDY; KIDNEY POLYCYSTIC DISEASE; LIVER REGENERATION; NONHUMAN; PNEUMONIA; PROSTATE CANCER; RESTENOSIS; RETINOPATHY; REVIEW; RNA HYBRIDIZATION; RNA PROCESSING; RNA TRANSLATION; SEQUENCE ANALYSIS; SOLID TUMOR; THALASSEMIA; VASCULAR DISEASE; VIRUS INFECTION;

ANIMALS; CARBOHYDRATE SEQUENCE; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

ANIMALIA;

EID: 4844225667     PISSN: 13892010     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389201043376706     Document Type: Review

References (82)

1. Dias, N. and Stein, C.A. (2002) Mol. Cancer Ther., 5, 347-55
2. Crooke, S.T. (2000) Methods Enzymol., 313, 3-45.
3. Orr, R.M. (2001) Curr. Opin. Mol. Ther., 3, 288-94.
4. Devi, G.R. (2002) Curr. Opin. Mol. Ther., 4(2), 138-48.
5. Pirollo, K.F.; Rait, A.; Sleer, L.S. and Chang, E.H. (2003) Pharmacol. Ther., 99(1), 55-77.
6. Iversen, P.L.; Copple, B.L. and Tewary, H.K. (1995) Toxicol. Lett., 82-83, 425-30.
7. Levin, A.A. (1999) Biochim. Biophys. Acta., 1489(1), 69-84.
8. Kreig, A.M. (1999) Biochim. Biophys. Acta., 1489(1), 107-16
9. Henry, S.P.; Novotny, W.; Leeds, J.; Auletta, C. and Kornbrust, D.J. (1997) Antisense Nucleic Acid Drug Dev., 7(5), 503-10.
10. Iversen, P.L.; Cornis, K.G.; Iversen, L.J.; Mata, J.E. and Bylund, D.B. (1999) Toxicol. Appl. Pharmacol., 160(3):289-96.
11. Burgess, T.L.; Fisher, E.F.; Ross, S.L.; Bready, J.V.; Qian, Y.; Bayewitch, L.A.; Cohen, A.M.; Herrera, C.J.; Hu, S.S.; Kramer, T.B.; Lott, F.D.; Martin, F.H.; Pierce, G.F.; Simonet, L. and Farrell C.L. (1995) Proc. Natl. Acad. Sci. U S A, 92(9), 4051-5.
12. Copple, B.L.; Gmeiner, W.M. and Iversen, P.L. (1995) Toxicol. Appl. Pharmacol., 133(1), 53-63.
13. Mata, J.E.; Bishop, M.R.; Tarantolo, S.R.; Angel, C.R.; Swanson, S.A. and Iversen, P.L. (2000) J. Toxicol. Clin. Toxicol., 38(4), 383-7.
14. Summerton, J. and Weller, D. (1997) Antisense Nucleic Acid Drug Dev. 7(3), 187-95.
15. Summerton, J. and Weller, D. (1997) Nucleosides Nucleotides., 16(7), 889-898.
16. Iversen, P.L. (2001) Curr. Opin. Mol. Ther., 3(3), 235-8.
17. Summerton, J.; Stein, D.; Huang, S.B.; Matthews, P.; Weller, D. and Partridge, M. (1997) Antisense Nucleic Acid Drug Dev., 7(2), 63-70.
18. Hudziak, R.M.; Summerton, J.; Weller, D.D. and Iversen, P.L. (2000) Antisense Nucleic Acid Drug Dev., 10(3): 163-76.
19. Summerton, J. (1999) Biochim. Biophys. Acta., 1489(1), 141-58.
20. Stein, C.A. (2000) Pharmacol. Ther., 85(3), 231-6.
21. Stein, D.; Foster, E.; Huang, S.B.; Weller, D. and Summerton, J. (1997) Antisense Nucleic Acid Drug Dev., 7(3), 151-7.
22. Giles, R.V.; Spiller, D.G.; Clark, R.E. and Tidd, D.M. (1999) Antisense Nucleic Acid Drug Dev., 9(2), 213-20.
23. Sazani, P. and Kole, R. (2003) J. Clin. Invest., 112(4), 481-6.
24. Ghosh, C.; Stein, D.; Weller, D. and Iversen, P.L. Methods Enzymol., 313, 135-43.
25. Hudziak, R.M.; Barofsky, E.; Barofsky, D.F.; Weller, D.L.; Huang, S.B. and Weller, D.D. (1996) Antisense Nucleic Acid Drug Dev., 6(4), 267-72.
26. Wolf, J.A.; Malone, R.W. and Williams, P. (1990) Science, 247, 1465-1468.
27. Feinberg, M.B.; Jarret, R.F.; Aldovini, A; Gallo, R.C. and Wong-Staal, F. (1986) Cell, 46, 807-817.
28. Sodroski, J.; Goh, W.C.; Rosen, D.; Dayton, A.; Terwilliger, E. and Haseltine, W. (1986) Nature (London)., 321, 412-417.
29. Stahel, R.A.and Zangemeister-Wittke, U.(2003) Lung Cancer., 41 (Suppl 1), S81-8.
30. Stein, C.A. (1999) Biochim Biophys Acta., 1489(1), 45-52.
31. Tari, A. M. and Lopez-Berestein, G. (2001) Curr. Opin. Investig. Drugs., 2(10), 1450-3.
32. Thierry, A.R.; Vives, E.; Richard, J.P.; Prevot, P.; Martinand-Mari, C.; Robbins, I. and Lebleu, B. (2003) Curr. Opin. Mol. Ther., 5(2):133-8.
33. Lebedeva, I.; Benimetskaya, L.; Stein, C.A. and Vilenchik, M. (2000) Eur. J. Pharm. Biopharm., 50(1), 101-19.
34. Ghosh, C. and Iversen, P.L. (2000) Antisense Nucleic Acid Drug Dev., 10(4), 263-74.
35. Arora, V.; Cate, M.L.; Ghosh, C. and Iversen, P.L. (2002) Drug Metab. Dispos., 30(7):757-62.
36. Devi, G.R.; Oldenkamp, J.R.; London, C.A. and Iversen, P.L. (2002) Prostate., 53(3), 200-10.
37. Partridge, M.; Vincent, A.; Matthews, P.; Puma, J.; Stein, D. and Summerton, J. (1996) Antisense Nucleic Acid Drug Dev., 6(3), 169-75.
38. Morcos, P.A. (2001) Genesis., 30(3), 94-102.
39. Suwanmanee, T.; Sierakowska, H.; Lacerra, G.; Svasti, S.; Kirby, S.; Walsh, C.E.; Fucharoen, S. and Kole, R. (2002) Mol. Pharmacol., 62(3), 545-53.
40. Heasman, J. (2002) Dev. Biol., 243(2), 209-14.
41. Corey, D.R. and Abrams, J.M. (2001) Genome Biol., 2(5):REVIEWS1015. Epub
42. Ekker, SC. (2000) Yeast., 17(4), 302-306.
43. Nasevicius, A. and Ekker, S.C. (2000) Nat. Genet., 26(2), 216-20.
44. Arora, V.; Knapp, D.C.; Smith, B.L.; Statdfield, M.L.; Stein, D.A.; Reddy, M.T.; Weller, D.D. and Iversen, P.L. (2000) J. Pharmacol. Exp. Ther. 292(3), 921-8.
45. Arora, V. and Iversen, P.L. (2000) Drug Metab. Dispos., 28(2), 131-8.
46. Ricker, J.L.; Mata, J.E.; Iversen, P.L. and Gattone, V.H. (2002) Kidney Int., 61 (Suppl. 1), 125-131.
47. Kipshidze, N.; Keane, E.; Stein, D.; Chawla, P.; Skrinska, V.; Shankar, L.R.; Khanna, A.; Komorowski, R.; Haudenschild, C.; Iversen, P.; Leon, M.B.; Keelan, M.H. and Moses, J. (2001) Catheter Cardiovasc. Interv., 54(2), 247-56.
48. Kipshidze, N.; Moses, J.; Shankar, L.R. and Leon, M. (2001) Curr. Opin. Mol. Ther., 3(3), 265-77.
49. Kipshidze, N.; Iversen, P.; Keane, E.; Stein, D.; Chawla, P.; Skrinska, V.; Shankar, L.R.; Mehran, R.; Chekanov, V.; Dangas, G.; Komorowski, R.; Haudenschild, C.; Khanna, A.; Leon, M.; Keelan, M.H. and Moses, J. (2002) Cardiovasc. Radiat. Med., 3(1), 26-30.
50. Kipshidze, N.N.; Kim, H.S.; Iversen, P.; Yazdi, H.A.; Bhargava, B.; New, G.; Mehran, R.; Tio, F.; Haudenschild. C.; Dangas, G.; Stone, G.W.; Iyer, S.; Roubin, G.S.; Leon, M.B. and Moses, J.W. (2002) J. Am. Coll. Cardiol., 39(10), 1686-91.
51. Iversen, P.L.; Arora, V.; Acker, A.; Mason, D.H. and Devi, G.R. (2003) Clin. Cancer Res., 9(7), 2510-9.
52. Knapp, D.C.; Mata, J.E.; Reddy, M.T.; Devi, G.R. and Iversen, P.L. (2003) Anticancer Drugs., 14(1):39-47.
53. London, C.A.; Sekhon, H.S.; Arora, V.; Stein, D.A.; Iversen, P.L. and Devi, G.R. (2003) Cancer Gene Therapy., in press.
54. London, C.A.; Knapp, D.C.; Ko, Y.J.; Balk, S.; DeSouza, M.; Farrell, D.H.; Iversen, P.L. and Devi, G.R. (2002) Cancer Gene Therapy, 10(Suppl 1), S3.
55. Qin, G.; Taylor, M.; Ning, Y.Y.; Iversen, P. and Kobzik, L. (2000) Antisense Nucleic Acid Drug Dev., 10(1), 11-6.
56. Arora, V.; Knapp, D.C.; Reddy, M.T.; Weller, D.D. and Iversen, P.L. (2002) J Pharm. Sci., 91(4), 1009-18.
57. Arora, V.; Hannah, T.L.; Iversen, P.L. and Brand, R.M. (2002) Pharm. Res., 19(10), 1465-70.
58. Arora, V. and Iversen, P.L. (2001) Curr. Opin. Mol. Ther. 3(3), 249-57.
59. McCaffrey, A.P.; Meuse, L.; Karimi, M.; Contag, C.H. and Kay, M.A. (2003) Hepatology, 38(2), 503-8.
60. Stein, C.A.; Iversen, P.L.; Subasinghe, C.; Cohen, J.S.; Stec, W.J. and Zon, G. (1990) Anal. Biochem., 188, 11-16
61. Nicklin, P.L.; Craig, S.J. and Phillips, J.A. (1998) in Antisense Research and Application (Crooke, S.T., Ed.), Springer-Verlag, New York, pp. 141-168.
62. Wallace, T.L.; Cossum, P.A. and Cameron, P.A. (1998) in Applied Antisense Oligonucleotide Technology, (Stein, C.A and Krieg, A.M. Eds.) Wiley-Liss, Inc., pp. 407-429.
63. Iversen, P. (1991) Anti-Cancer Drug Design, 6: 531-538.
64. Cossum, P.A.; Sasmor, H.; Dellinger, D.; Truong, L.; Cumms, L.; Owens, S.R.; Markham, P.M.; Shea, J.P. and Crooke, S.T. (1993) J. Pharmacol. Exp. Ther., 267, 1181-1190.
65. Cossum, P.A.; Truong, L.; Owens, S.R.; Markham, P.M.; Shea, J.P. and Crooke, S.T. (1994) J. Pharmacol Exp. Ther., 269, 89-94.
66. Iversen, P.L.; Mata, J.; Tracewell, W.G. and Zon, G. (1994) Antisense. Res. Dev., 4, 43-52.
67. Zhang, R.; Diasio, R.B.; Lu, Z.; Liu, T.; Jiang, Z.; Galbraith, W.M. and Agrawal S. (1995) Biochem. Pharmacol., 49, 929-939.
68. Zhang, R.; Lu, Z.; Zhang, X.; Zhao, H.; Diasio, R.B.; Liu, T.; Jiang, Z. and Agrawal, S. (1995) Clin. Chem. 41, 836-843.
69. Agrawal, S. and Temsamani, J. (1996) in Methods in Molecular Medicine: Antisense Therapeutics, (Agrawal, S., Ed.), Humana Press Inc. Totowa, NJ, pp. 247-270.
70. Bishop, M.R.; Iversen, P.L.; Bayever, E.; Sharp, J.G.; Greiner, T.C.; Copple, B.L.; Ruddon, R.; Zon, G.; Spinolo, J.; Arneson, M.; Armitage, J.O. and Kessinger, A. (1996) J. Clin. Oncol., 14 (4), 1320-6.
71. Geary, R.S.; Yu, R.Z.; Leeds, J.M.; Watanabe, T.A.; Henry, S.P.; Levin, A.A. and Templin, M.V. (2001) in Antisense Drug Technology Principles, Strategies, and Applications (Crooke, S.T., Ed.), Marcel Dekker, Inc. New York, pp. 119 pp.119-154.
72. Agrawal, S. and Zhang, R. (1997) Ciba Foundation Symposium 209, Wiley, Chichester, pp. 60-78.
73. Iversen, P.L. (2001) in Antisense Drug Techcology- Principles, Strategies, and Applications, (Crooke, S.T., Ed.), Marcel Dekker, Inc., New York, pp. 375-389.
74. Stein, D.A.; Skilling, D.E.; Iversen, P.L. and Smith, A.W. (2001) Antisense Nucleic Acid Drug Dev., 11(5), 317-25.
75. Smith, A.W.; Matson, D.O.; Stein, D.A.; Skilling, D.E.; Kroeker, A.D.; Berke, T. and Iversen, P.L. (2002) Curr. Opin. Mol. Ther., 4(2), 177-84.
76. Jubin, R.; Vantuno, N.E.; Kieft, J.S, ; Murray, M.G.; Doudna, J.A.; Lau, J.Y. and Baroudy, B.M. (2000) J. Virol., 74(22), 10430-7.
77. Jubin, R. (2001) Curr. Opin. Mol. Ther., 3(3):278-87.
78. Taylor, M.F.; Weller, D.D. and Kobzik, L. (1998) Antisense Nucleic Acid Drug Dev., 8(3), 199-205.
79. Zhang, S.; Ren, J.; Khan, M.F.; Cheng, A.M.; Abendschein, D. and Muslin, A.J. (2003) Arterioscler. Thromb. Vasc. Biol., 3 [Epub ahead of print].
80. Monga, S.P.; Monga, H.K.; Tan, X.; Mule, K.; Pediaditakis, P. and Michalopoulos, G.K. (2003) Gastroenterology, 124(1), 202-16
81. Kaneko, K.; Satoh, K.; Masamune, A.; Satoh, A. and Shimosegawa, T. (2002) Pancreas, 24(3), 251-7.
82. Lacerra, G.; Sierakowska, H.; Carestia, C.; Fucharoen, S.; Summerton, J.; Weller, D. and Kole, R. (2000) Proc. Natl. Acad. Sci. U S A, 97(17), 9591-6.